London’s Unravel Health raises €2.96 million to help women track hormones at home with a palm-sized lab
Unravel Health, a London-based startup developing technology to measure hormones at home daily, has raised €2.96 million (£2.5 million) to develop the Micro Lab, a palm-sized device that reads multiple hormones from a saliva sample in minutes.
The round was led by Conduit EIS Impact Fund and Wrightwood, joined by Leo Capital, Embryo Ventures, Hermesa and returning investor Zinc VC.
“People said nobody could climb Everest without oxygen, until someone did. Reading hormones in saliva outside a lab has been our Everest. Fifteen years ago I built my own hormone tracker to manage PCOS (now PMOS), because a blood test told me almost nothing about what my body was doing. Soon anyone will be able to bring the lab home to understand their symptoms,” said Veronika Bridgman, co-founder and CEO of Unravel Health.
Founded in 2024 by Bridgman, Liza Levy (CCO) and Dr. Alexandra Oti (CMO), Unravel Health is a women’s health startup aiming to build the data layer for hormone-linked health.
Saliva carries the hormones the body uses, but in quantities so small that only a lab could measure them, the UK startup explains. Unravel claims that its technology, developed over ten years at the University of Glasgow and protected by three granted patents, aims to bring that lab into the home.
Women’s health rarely comes down to one hormone, so the Micro Lab is being built to read oestradiol, the main form of oestrogen, alongside three other key hormones simultaneously.
The company says hormones shift throughout the month, but a blood test captures a single day. Wearables track every day but can only estimate hormone levels. It notes that the Micro Lab is designed to sit between the two, giving real hormone readings at home, day after day, at every stage of life from puberty to perimenopause,” the company mentioned in the press release.
Eva-Maria Dimitriadis, Managing Partner at Conduit EIS Impact Fund, said, “Women’s hormonal health is one of the largest under-served markets in healthcare, and the bottleneck has always been data. Unravel is solving a hard technical problem that many are trying to address: measuring multiple hormones accurately, longitudinally, and affordably. And they are doing it via saliva, at home, aiming for lab-grade sensitivity. The team pairs deep science with a clear view of what women and clinicians actually need. We’re proud to lead this round and back them from a very early stage.”
The round builds on more than €1.18 million (£1 million) from Innovate UK, the Medical Research Council, SBRI, strategic angels and Zinc. It completed a first close of over €2.36 million (£2 million) on 14th October and will close with final investors in the coming weeks.
The funding will fund external equivalency studies, the development of additional markers, and the start of the regulatory approval process. The round will take the Micro Lab to its first early-access devices in 2027, through partners in pharmacy, digital health, and clinical research.
Women’s hormones are the first application. The underlying technology has already been used to measure other markers, such as those for heart health and prostate cancer, and could bring many more lab tests into the home.
